ALDA Receives Registration for Hydrocortisone Ointment
08 Settembre 2011 - 3:15PM
Marketwired
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) (the
"Company" or "ALDA") announces that Natural Product Number ("NPN")
80026033 has been issued for a 0.5% hydrocortisone (0.5% HC)
ointment. The Company is authorized to sell this product in Canada
for temporary relief of minor skin irritations, rashes, itching and
redness due to eczema, insect bites, poison ivy and other
irritating plants; contact dermatitis caused by soaps, detergents,
cosmetics, jewellery and other materials that irritate the skin;
seborrheic dermatitis and psoriasis.
Typically, skin conditions of these types (which affect over 75%
of Canadian adults at one time or another) begin as an inflammatory
condition, but are often worsened or prolonged by secondary
infection with bacteria or fungi (such as the fungi that causes
athlete's foot). The combination of an effective anti-microbial
product (such as the T36® formulation) with an anti-inflammatory
agent (such as 0.5% hydrocortisone) would address this common
medical condition more effectively and make treatment
recommendations more straightforward for the health care provider
and much easier to carry out for the patient. This innovative
combination of an anti-microbial and anti-inflammatory therapy
(avoiding the need to apply separate products to treat a single
condition) represents an important step forward in the
non-prescription therapeutic market. It is also consistent with the
current approach favoured by a number of health providers
encouraging Canadians to take charge in a positive way of their own
care. Obtaining registration of a hydrocortisone ointment is a
first step for the Company in bringing this approach to market.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control
therapeutics derived from its patented T36® technology. The Company
trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements:
Information in this press release that involves ALDA's
expectations, plans, intentions or strategies regarding the future
are forward-looking statements that are not facts and involve a
number of risks and uncertainties. ALDA generally uses words such
as "outlook", "will", "could", "would", "might", "remains"," "to
be", "plans", "believes", "may", "expects", "intends",
"anticipates", "estimate", "future", "plan", "positioned",
"potential", "project", "remain", "scheduled", "set to", "subject
to", "upcoming", and similar expressions to help identify
forward-looking statements. The forward-looking statements in this
release are based upon information available to ALDA as of the date
of this release, and ALDA assumes no obligation to update any such
forward-looking statements. Forward-looking statements believed to
be true when made may ultimately prove to be incorrect. These
statements are not guarantees of the future performance of ALDA and
are subject to risks, uncertainties and other factors, some of
which are beyond its control and may cause actual results to differ
materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor
Relations 604-377-5781 or 604-521-8300 Ext. 203 604-521-8322 (FAX)
scott_young@aldacorp.com www.aldacorp.com
Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Giu 2023 a Giu 2024